Effect of highly dosed molsidomine on restenosis rate after coronary angioplasty: A randomized placebo-controlled double-blind trial  by Wöhrle, Jochen et al.
. 
78A ABSTRACTS - Angiography & Interventional Cardiology 
dence of TCP (14.1% “s 4.4%, p=O.OOZ) and profound TCP (5.6% “s 1.6%, p=O.O36). 
Four to 8 weeks after readministration, 27.4% of patients were noted to have a positive 
HACA titer, which decayed with time with a half life of 4.1 months (95% Cl 3.4-5.2). The 
rates of procedural success, bleeding, TCP, or other adverse events were not different in 
the 196 patients receiving 3 or more abciximab administrations. 
Conclusion: Readministration of abciximab can be accomplished without severe allergic 
responses and with a safety and efficacy profile similar to ftrst time adminlstration. How- 
ever, the rate of profound TCP appears to be increased, particularly when the time 
between administrations is short (eg ~30 days) and when HACA titers are present. 
9:00 am. 
867-3 Effect of Highly Dosed Molsidomine on Restenosis Rate 
After Coronary Angioplasty: A Randomized Placebo- 
Controlled Double-Blind Trial 
Jochen Wdhrle, Thorsten Nusser, Hans A. Kestler, Olaf Grebe, Vinzenz Hornbach. 
Martin HOher, Matthias Kochs, University of Ulm, Ulm, Germany 
Background: SIN-l lnhiblts the expression of P-selectin and GP Ilb/llla receptor, sup- 
presses the activation of GP Ilb/llla and inactivates already stimulated GP llb/llla recap- 
tars. In addition, the migration and proliferation of smooth muscle cells is inhibited. The 
active metabolite of molsidomine is SIN-l. 
Methods: We studied the effect of the NO-donor molsidomine (3xamgldie) on restenosis 
rate in a randomized, placebo controlled double-blind trial in patients with de-now 
lesions. The study medication was started after randomization 3 days before PTCA in 
166 patients. 
Results: Both groups (molsidomine vs placebo) did not differ in frequency of LAD lesion 
42% vs 38%, AHA type 82/C lesions 57% YS 51%, provisional stenting 28% vs 25%, dia- 
betes mellitus 18% vs 12%. Angiographic follow-up was performed after 171+32 days. 1 
patient was lost to follow-up. There was no death or myocardial infarction during follow- 
up. According to intention to treat, 90 lesions in the molsidomine group and 97 lesions in 
the placebo group were analyzed. QCA data showed no difference between both groups 
in terms of (molsidomine vs placebo [mm]): MLD pre PTCA 0.75kO.36 vs 0.76+0.35; 
MLD post angioplasty 2.24eO.51 vs 2.2liO.51; MLD at follow-up 1.65~0.75 vs 
1.67~0.77; reference diameter post angioplasty 2.99eO.52 vs 2.95t0.56. Late loss index 
was 0.39kO.53 in the molsidomine group and 0.37eO.47 in the placebo group. Resteno- 
sis rate defined as >50% diameter stenosis at follow-up angiography was 25.6% in the 
molsldomine group and 29.9% in the placebo group (difference between groups 4.3%; 
95% Cl -8.5% to 16.9%, ns). Re-intervention rate (re-angioplasty, CABG) did not differ 
between both groups. Patients receiving molsidomine had less angina1 pain at follow-up 
(improvement in angina1 class from PTCA to follow-up CCS 1.4iO.9 vs l.OeO.9; 
p=O.O26). During 12 months follow-up the frequency of major adverse cardiac events 
(MACE) was not different. 
Conclusion: Although molsidomine inhibits via SIN-l smooth muscle cells and the GP Ilb/ 
llla receptor in several ways, treatment with molsidomine for 6 months after coronary 
angioplasty has no effect on angiographic restenosis rate. re-intervention rate or occur- 
rence of MACE. 
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667-4 A Higher Vascular Injury Index Is Associated With a 
Higher Incidence of In-Stent Restenosis: Insights From 
the PRESTO Trial 
Abid R. Assali, Ali Moustapha, Hany Awadalla, Joseph G. Salloum, Robyn McClelland. 
Richard W. Smalling, University of Texas Medical School at Houston, Houston, TX, 
Louisiana State University, Shreveport, LA 
Background: High-pressure adjunctive balloon angioplasty (PTCA) with antiplatelet 
therapy nearly abohshed stent thrombosis. High-pressure PTCA may however be associ- 
ated with more late lumen loss. Objective: Using the large PRESTO database, we 
sought to evaluate the correlation between vascular injury Index and in-stent restenosis 
(ISR) after stent implantation. Methods: The PRESTO trial randomized 11,500 pts. 
1 ,I 23 pts underwent angiographic follow-up, and were included in our study. Vascular 
injury index was defined as: (Balloon diameter/vessel diameter) x balloon length x infla- 
tion pressure x duration of inflation in seconds x number of inflations. Pts were divided 
into tertile groups according to the vascular injury index (mild, moderate and severe). 
Baseline parameters, in-hospital and follow-up (9 months) events were compared. 
Results: Pts in the severe injury group had longer lesions and a higher incidence of 
intracoronary dissections. At follow-up, pts with moderate and severe vascular injury had 
a significantly higher incidence of angiographic ISR, compared to those with mild injury. 
In multivariate analysis, after adjusting for baseline differences, both moderate and 
severe vascular injury were associated with a higher incidence of angiographic ISR (OR 
= 1.76, 95% Cl =1.26-2.45, pcO.001, and OR = 1.75, 95% Cl =1.19-2.58, p=O.O04 
respectively). Conclusion: High-pressure PTCA with moderate or severe vascular injury 
may lead to a higher incidence of ISR. 
Mild Injury Moderate Injury Severe Injury P 
IfldeX Index Index 
(N=385) (Nz372) (N=366) 
Ml IO (3%) 4 (1%) 7 (2%) 0.3 
TVR 56 (15%) 52 (14%) 67 (18%) 0.2 
Death 1 (0%) 0 (0%) 1 (0%) 0.6 
Angiographic 147 (36%) 179 (48%) 164 (50%) 0.002 
ISR 
MACE 167 (43%) 193 (52%) 199 (54%) 0.008 
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867-5 ’ Abciximab Upregulates the Number of Glycoprotein Ilb/ 
llla Receptors/n Viva 
Ramin Artang Gitte W. Jurgensen, Niels J. Frandsen, Ulrik Abildgaard, Jorn D. Nielsen, 
Shereif Rezkalla, Gent&e University Hospital, Hellerup, Denmark, Marshfield Clinic, 
Marshfield, WI 
Background: The GUSTO IV-ACS study showed no benefits from abciximab (AB) in 
noninvasively managed patients. An upregulation of glycoprotein (GP) Ilb/llla receptors 
on platelets has been reported when AB is added to blood in vitro. The aim of this study 
was to observe whether AB increases the number of GPllb/llla receptors in viva. 
Methods: Eighteen consecutive patients who underwent percutaneous coronary angio- 
plasty with stent placement were included. All patients received heparin during catheter- 
ization and were continued on aspirin and clopidogrel. Ten patients received AB (bolus of 
0.25 mglkg and 0.125 p glkglmin infusion for 12 hours) based on interventionist’s deci- 
sion after stent placement. The other 8 patients served as controls. Blood was drawn at 
baseline, 2, 8, 24, and 48 hours following bolus infusion of AB, and at same intervals fol- 
lowing the periprocedural heparin infusion in the control group. Platelets were labeled 
with antibodies against CD41 (clone 5222. non-fibrinogen ligand of GPllb/llla) and ana- 
lyzed by flow cytometry Percent changes in the number of receptors at each time point 
were compared. 
Results: see figure 
Conclusion: Abciximab increases the number of GPllb/llla receptors on platelets signifi- 
cantly. Such an increase in the number of these receptors may be one mechanism 
behind the negative results of the GUSTO IV-ACS trial, as well as postprocedural coro- 
nary adverse events despite GPllb/llla inhibition. The clinical relevance of this finding 
requires further investigation. 
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Percutaneous Coronary Interventions in Octogenarians 
With Use of Glycoprotein GP llb/llla Inhibitors: Similar 
Major Adverse Cardiac Events but Higher Hemorrhagic 
Stroke Rate Than Younger Patients 
loannis lakovou George Dangas, Roxana Mehran, Gary S. Mintz, Alexandra J. Lansky, 
Edward M. Kreps, Michael B. Collins. lssam Moussa, Lynne A. Glasser, Gregg W. Stone, 
Martin B. Leon, Jeffrey W. Moses, Cardiovascular Research Foundation. New York, NY 
Background. Previous studies of percutaneous coronary interventions (PCI) in elderly 
patients and especially octogenarians, demonstrate increased in-hospital mortality. How- 
ever, it is unknown whether this risk profile persists when glycoprotein (GP) Ilb/llla inhib- 
itors are used during PCI. 
Methods. We identified 1369 consecutive patients who received GP Ilb/llla inhibitors 
during 1461 procedures. Of these, 93 (6.8%) were octogenarians (96 procedures)(mean 
age: 83 +/- 2 vs. 61 +I- 10 for the < 80 years group). 
Results. Baseline characteristics were similar between the two groups. There were no 
significant differences regarding the angiographic characteristics except from a higher 
rate of calcification (p&0001) and a smaller reference vessel diameter (p=O.OZ) of the 
octogenarian group. No statistically significant differences were observed in major vascu- 
lar complications. 
The two groups had similar procedural success and in-hospital major adverse cardiac 
event (MI, death, urgent revascularization) rate (see Table). However, octogenarians had 
a higher rate of in-hospital neurologic events due to hemorrhagic stroke (2.1% vs. O.l%, 
p=0.02) 
Conclusions. Procedural success and in-hospital cardiac outcomes of octogenarians 
undergoing PCI with GP Ilb/llla inhibitors are similar to those < 80 years old. This favour- 
able effect is achieved at the expense of higher rate of in-hospital hemorrhagic stroke. 
Procedural and m-hospital ~utc~rne 
Procedural Success 
In-hospital Q-wave Ml 
In-hospital MACE 
In-hospltalNeurologic Events (hemmorhagic 
stroke) 
~80 <80 P value 
YEARS YEARS 
98% 99% 0.1 
0 0 1.0 
2.1% 0.7% 0.1 
2.1% 0.1% 0.02 
